Cargando…
Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions
Current pharmacotherapy of Parkinson’s disease (PD) is symptomatic and palliative, with levodopa/carbidopa therapy remaining the prime treatment, and nevertheless, being unable to modulate the progression of the neurodegeneration. No available treatment for PD can enhance the patient’s life-quality...
Autores principales: | Behl, Tapan, Kaur, Gagandeep, Bungau, Simona, Jhanji, Rishabh, Kumar, Arun, Mehta, Vineet, Zengin, Gokhan, Brata, Roxana, Hassan, Syed Shams ul, Fratila, Ovidiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504186/ https://www.ncbi.nlm.nih.gov/pubmed/32872273 http://dx.doi.org/10.3390/ijms21176235 |
Ejemplares similares
-
Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer’s Disease
por: Behl, Tapan, et al.
Publicado: (2020) -
Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives
por: Behl, Tapan, et al.
Publicado: (2020) -
Dysregulation of the Gut-Brain Axis, Dysbiosis and Influence of Numerous Factors on Gut Microbiota Associated Parkinson’s Disease
por: Kaur, Gagandeep, et al.
Publicado: (2021) -
Flavonoids, the Family of Plant-Derived Antioxidants Making Inroads into Novel Therapeutic Design Against Ionizing Radiation-Induced Oxidative Stress in Parkinson’s Disease
por: Behl, Tapan, et al.
Publicado: (2022) -
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review
por: Behl, Tapan, et al.
Publicado: (2021)